Appointed
Jordan N. Freeman
Chief Accounting Officer
NRC ·
NRC HEALTH
appointed Jordan N. Freeman as the Company’s Chief Accounting Officer.
Ready 8-Ks
41
Latest filing
June 29, 2026, 1:04 PM ET
Top materiality
0.80
Event mix
earnings ×20 · leadership ×9 · other_material ×6
Sentiment
11 pos · 6 neg · 24 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for NRC
Highest-materiality recent filing
NRC Q4 2023 EPS $0.36; CFO Karas to retire March 31, dividend $0.12
- Q4 2023 diluted EPS $0.36 vs $0.27; prior year included $0.10 Canadian exit charge.
- Revenue flat at $38M as new core sales offset non-core revenue declines.
-
Shareholders approved removing supermajority voting requirements (19.0M for, 0.97M against).
-
NRC Health Q1 revenue up 4% to $34.8M; TRCV record $152.1M (+13% YoY)
GAAP net income $3.2M ($0.14 diluted EPS); adjusted net income $4.6M ($0.21 adjusted diluted EPS).
-
NRC Health amends exec stock awards, eliminates repurchase right; expects $9.4M Q2 expense
Committee amended grants to CEO Trent Green (500k shares), COO Helen Hrdy (100k), and Chief Corp Dev Officer Andrew Monich (100k) to eliminate repurchase right.
-
NRC Health declassifies board, formalizes name change; CFO restricted stock amended
Name changed to NRC Health from National Research Corp; 'NRC' ticker unchanged; no shareholder vote required.
-
NRC Health TRCV reaches all-time high of $152M, up 13% YoY
TRCV surpassed $152 million as of March 4, 2026, a new all-time high for NRC Health.
-
NRC Health Q4 2025 revenue $35.2M; TRCV up 8% YoY to $144.1M
Q4 GAAP net income $1.8M ($0.08 diluted EPS); adjusted net income $3.4M ($0.16 diluted EPS).
-
NRC Health Q3 2025: TRCV up 8% to $141.7M; Adj EBITDA +11% YoY to $10.9M
Revenue $34.6M (+2% QoQ); GAAP net income $4.1M (12% of revenue); Adj net income $5.0M (14% of revenue).
-
NRC Health names Shane Harrison CFO effective Sept 25, 2025
Shane Harrison appointed Executive VP and CFO, succeeding Michael D. Hays as principal financial officer.
-
NRC Health Q2 2025: TRCV grows 2% sequentially; net margin 0% on exec comp; adj EBITDA margin 30%
TRCV grew 2% sequentially, third consecutive quarter of growth and highest since Q1 2021.
-
National Research shareholders approve 2025 Omnibus Incentive Plan, elect directors
Donald M. Berwick and Stephen H. Lockhart elected as directors for three-year terms.
-
National Research Corporation Reports Q1 2025 Results and Announces Share Repurchase Program
Total recurring value contract value increased sequentially for second consecutive quarter.
-
National Research designates CEO Hays as interim PFO, appoints Freeman as CAO
CEO Michael D. Hays designated principal financial officer; will serve as PEO and PFO until Trent Green becomes CEO on June 1, 2025.
-
NRC adjusts exec compensation ahead of CEO transition; COO gets 100k share grant
Trent Green to become CEO and director effective June 1, 2025, as previously announced.
-
NRC appoints Trent Green as CEO effective June 1, 2025; Hays becomes Chairman
Trent Green named CEO effective June 1, 2025; current CEO Mike Hays transitions to Chairman.
-
New credit agreement dated Feb 6, 2025 amends and restates 2020 facility with First National Bank of Omaha.
-
NRC Q4 revenue $36.9M, EPS $0.28; CTO Louvion resigns
Q4 revenue $36.9M vs $38.0M YoY; diluted EPS $0.28 vs $0.36.
-
National Research CFO/PAO Linda Stacy to retire effective Dec 31, 2024
Linda Stacy notified company of retirement as Secretary, Principal Financial Officer, and Principal Accounting Officer.
-
NRC Health Q3 revenue falls 5.5% to $35.8M; EPS drops to $0.24 from $0.32
Revenue $35.8M vs $37.9M a year ago; diluted EPS $0.24 vs $0.32.
-
National Research appoints Helen L. Hrdy as COO effective Oct 14, 2024
Helen L. Hrdy, 60, appointed Chief Operating Officer on October 14, 2024.
-
NRC Health Q2 revenue $35M, EPS $0.26; amends credit; acquires NOBL Health
Q2 revenue ~$35M vs ~$36M YoY; diluted EPS $0.26 vs $0.29 YoY; TRCV $138M at June 30.
-
NRC shareholders elect directors, ratify KPMG, approve say-on-pay at annual meeting
Michael D. Hays re-elected with 97.1% of votes cast; John N. Nunnelly with 91.2%.
-
NRC Health appoints Linda Stacy as PFO; Q1 dividend $0.12; $40M net debt; no GAAP results disclosed
Linda Stacy appointed Principal Financial Officer effective May 7, 2024; retains roles as PAAO and Secretary.
-
NRC Q4 2023 EPS $0.36; CFO Karas to retire March 31, dividend $0.12
Q4 2023 diluted EPS $0.36 vs $0.27; prior year included $0.10 Canadian exit charge.
-
Helen Hrdy promoted to CCO; Jason Hahn (CRO), Christophe Louvion (CPTO), Andy Monnich (CCDO) appointed.
-
COO Jona S. Raasch to depart role effective Dec 31, 2023; remains with company
On Dec 28, 2023, Jona S. Raasch notified company she would step down as COO.
-
National Research Q3 EPS $0.32 vs $0.33 YoY; HUP adopted by 91 orgs
Diluted EPS $0.32 for Q3 2023, down from $0.33 in Q3 2022.
-
National Research reports Q2 2023 diluted EPS $0.29, down from $0.33 YoY; new sales up 53%
Diluted EPS $0.29 for Q2 2023 vs $0.33 for Q2 2022, a 12% decrease.
-
NRC amends credit agreement to exclude HQ renovation capex from covenant, cap $25M
Second Amendment to Credit Agreement with First National Bank of Omaha dated June 16, 2023.
-
NRC annual meeting: all proposals pass with >96% support; directors elected for 3-year terms
Elected Parul Bhandari (98.15% for) and Penny A. Wheeler (96.55% for) as directors for three-year terms expiring 2026.
-
National Research Q1 EPS falls to $0.28 from $0.34; capital allocation unchanged
Diluted EPS $0.28 for Q1 2023, down from $0.34 in Q1 2022.
-
NRC Health reports Q4 EPS $0.27, down from $0.38; FY revenue +7% but EPS $1.27 vs $1.46
Q4 diluted EPS $0.27 (vs $0.38 in Q4 2021); full-year 2022 diluted EPS $1.27 (vs $1.46).
-
National Research Corp Q3 revenue flat at $37.7M; EPS down to $0.33 from $0.38
Revenue $37.7M vs $37.8M prior year; net income $8.3M vs $9.7M; diluted EPS $0.33 vs $0.38.
-
National Research increases delayed draw term loan commitment to $75M, extends maturities
Delayed draw-down term loan commitment raised from $15M to $75M.
-
NRC Health Q2 revenue up 2% to $37.3M; diluted EPS falls to $0.33 from $0.35
Revenue $37.3M (+2% YoY); net income $8.3M vs $8.9M; diluted EPS $0.33 vs $0.35.
-
NRC Health declares $0.24 quarterly dividend and authorizes up to 2.5M share repurchase
Quarterly dividend of $0.24 per share payable July 15, 2022; record date June 30, 2022.
-
NRC Health appoints Microsoft executive Parul Bhandari to Board of Directors
Parul Bhandari appointed as Class II director effective May 18, 2022, term through 2023 annual meeting.
-
National Research Corp Q1 revenue up 8% to $38.4M, EPS down to $0.34
Revenue $38.4M (+8% YoY), net income $8.5M vs $9.2M, diluted EPS $0.34 vs $0.36.
-
National Research Q4 revenue +10% to $38.3M, EPS $0.38; FY revenue +11% to $148.0M
Q4 2021 revenue $38.3M (+10% YoY); operating income $12.9M (+26%); diluted EPS $0.38 vs $0.32.
-
National Research Q3 revenue up 13% to $37.8M; EPS $0.38 vs $0.37
Revenue $37.8M (+13% YoY); operating income $13.1M (+9%).
-
National Research Q2 revenue up 17% to $36.4M; EPS rises to $0.35 from $0.30
Total Recurring Contract Value grew 5% YoY to $149.8M.
-
Shareholders approved reincorporation from Wisconsin to Delaware, effective June 30, 2021, with 93.68% of votes for.
Executive changes
Role change
(interim)
Michael D. Hays
principal financial officer
NRC ·
NRC HEALTH
designated Michael D. Hays, the Company’s Chief Executive Officer, to serve as the Company’s principal financial officer.
Appointed
Trent Green
Chief Executive Officer
NRC ·
NRC HEALTH
the board of directors of National Research Corporation, a Delaware corporation (the “Company”) appointed Trent Green as our Chief Executive Officer and to serve as a director, both effective June 1, 2025.
Appointed
(interim)
Linda Stacy
Interim Principal Financial Officer
NRC ·
NRC HEALTH
the Board appointed Linda Stacy to serve as Interim Principal Financial Officer until March 31, 2025
Role change
Micheal D. Hays
Chairman
NRC ·
NRC HEALTH
Micheal D. Hays, the Company’s current Chief Executive Officer, will transition to the role of Chairman
Appointed
Trent Green
Chief Executive Officer
NRC ·
NRC HEALTH
the Board appointed Trent Green as the Company’s Chief Executive Officer and to serve as a director, both effective June 1, 2025
Departed
Linda Stacy
Secretary, Principal Financial Officer, and Principal Accounting Officer
NRC ·
NRC HEALTH
On November 8, 2024, Linda Stacy, Secretary, Principal Financial Officer, and Principal Accounting Officer of National Research Corporation (the “Company”), notified the Company of her decision to retire effective December 31, 2024.
Appointed
Helen L. Hrdy
Chief Operating Officer
NRC ·
NRC HEALTH
On October 14, 2024, the Board of Directors of National Research Corporation, a Delaware corporation (the "Company"), appointed Helen L. Hrdy as the Company’s Chief Operating Officer.
Role change
Linda Stacy
Principal Financial Officer
NRC ·
NRC HEALTH
On May 7, 2024, the Company’s Board of Directors appointed Linda Stacy as the Company’s Principal Financial Officer.
Appointed
Linda Stacy
Principal Accounting Officer
NRC ·
NRC HEALTH
Also, on February 8, 2024, the Company’s Board of Directors approved the promotion of Linda Stacy, Vice President of Finance, to the position of Principal Accounting Officer, effective on March 31, 2024.
Departed
Kevin R. Karas
Chief Financial Officer
NRC ·
NRC HEALTH
On February 8, 2024, Kevin R. Karas, Senior Vice President, Chief Financial Officer, Treasurer and Secretary of the Company notified the Company of his decision to retire effective March 31, 2024.
Role change
Helen L. Hrdy
Chief Customer Officer
NRC ·
NRC HEALTH
On January 16, 2024, Helen L. Hrdy was promoted to the position of Chief Customer Officer of National Research Corporation, a Delaware corporation (the “Company”).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.55 · Most common event earnings